Brief: FDA Grants Vicore's Buloxibutid Fast Track for Pulmonary Fibrosis
29/01/2025 07:02
Jan 29 (Reuters) - Vicore Pharma Holding AB VICOR.ST :
* THE FDA GRANTS VICORE’S BULOXIBUTID FAST TRACK DESIGNATION
FOR
IDIOPATHIC PULMONARY FIBROSIS
* FAST TRACK DESIGNATION RECOGNIZES BULOXIBUTID'S POTENTIAL
FOR
IPF TREATMENT
Source text: ID:nMFN7qvNR
Further company coverage: VICOR.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Vicore Pharma Holding AB
See all newsBrief: Vicore Pharma Holding Q3 Net Revenues Amounted To Sek 0.6 Mln
Brief: Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results
Brief: Vicore Pharma Q2 Operating Loss At SEK 150.1 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:53 PM
Brief: Vicore Pharma Shares Start Trading In US On July 2